Advertisement

Expression and Targeting of Tumor Markers in Gelfoam® Histoculture: Potential Individualized Assays for Immuno-Oncology

  • Robert M. Hoffman
  • Fiorella Guadagni
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1760)

Abstract

Tumor-specific antigens are important in the study of tumor biology, tumor diagnosis, and prognosis and as targets for tumor therapy. This chapter reviews patient colon, breast, and ovarian tumors in 3-dimensional Gelfoam® histoculture maintaining in vivo-like expression of the important tumor antigens, for example TAG-72 and CEA. We have also reviewed that fluorescent antibodies can target tumors in Gelfoam® histoculture, thereby providing an assay for individual patients for sensitivity to therapeutic antibodies which have become so important in immuno-oncology and other cancer therapies.

Key words

Histoculture Gelfoam Tumor antigens Expression Monoclonal antibodies Targeting Immuno-oncology 

References

  1. 1.
    Colcher D, Horand-Hand P, Nuti M, Schlom J (1981) A spectrum of monoclonal antibodies reactive with human mannary tumor cells. Proc Natl Acad Sci 73:3199CrossRefGoogle Scholar
  2. 2.
    Horand-Hand P, Clocher D, Salomon D, Ridge J, Noguchi P, Schlom J (1985) Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein. Cancer Res 45:833–840Google Scholar
  3. 3.
    Guadagni F, Roselli M, Hoffman RM (1991) Maintenance of expression of tumor antigens in three-dimensional in vitro human tumor gel-supported histoculture. Anticancer Res 11:543–546PubMedGoogle Scholar
  4. 4.
    Guadagni F, Roselli M, Amato T, Cosimelli M, Mannella E, Perri P, Abbolito MR, Cavaliere R, Colcher D, Greiner JW, Schlom J (1991) Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. Cancer 68:2443–2450CrossRefPubMedGoogle Scholar
  5. 5.
    Freeman A, Hoffman RM (1986) In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci U S A 83:2694–2698CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM (1987) In vivo-like drug response of human tumors growing in three-dimensional, gel-supported, primary culture. Proc Natl Acad Sci U S A 84:5029–5033CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hoffman RM, Monosov AZ, Connors KM, Herrera H, Price JH (1989) A general native-state method for determination of proliferation capacity of human normal and tumor tissues in vitro. Proc Natl Acad Sci U S A 86:2013–2017CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Vescio RA, Connors KM, Youngkin T, Bordin GM, Robb JA, Umbreit JN, Hoffman RM (1990) Cancer biology for individualized cancer therapy: Correlation of growth fraction index in native-state culture with tumor grade and stage. Proc Natl Acad Sci U S A 87:691–695CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffman RM (1990) The distinction of small cell and non-small cell cancer by growth in native-state histoculture. Cancer Res 50:6095–6099PubMedGoogle Scholar
  10. 10.
    Hoffman RM (1991) Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3:86–92PubMedGoogle Scholar
  11. 11.
    Vescio RA, Connors KM, Kubota T, Hoffman RM (1991) Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci U S A 88:5163–5166CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Guadagni F, Li L, Hoffman RM (1992) Targeting antibodies to live tumor tissue in 3-D histoculture. In Vitro Cell Dev Biol 28A:297–299PubMedGoogle Scholar
  13. 13.
    Geller J, Sionit LR, Connors KM, Hoffman RM (1992) Measurement of androgen sensitivity in the human prostate in in vitro three-dimensional histoculture. Prostate 21:269–278CrossRefPubMedGoogle Scholar
  14. 14.
    Hoffman RM (1993) To do tissue culture in two or three dimensions? That is the question. Stem Cells 11:105–111CrossRefPubMedGoogle Scholar
  15. 15.
    Geller J, Sionit LR, Connors KM, Youngkin T, Hoffman RM (1993) Expression of prostate-specific antigen in human prostate specimens in in vitro three dimensional histoculture. In Vitro Cell Dev Biol 29A:523–524CrossRefGoogle Scholar
  16. 16.
    Furukawa T, Kubota T, Hoffman RM (1995) Clinical applications of the histoculture drug response assay. Clin Cancer Res 1:305–311PubMedGoogle Scholar
  17. 17.
    Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Hoffman RM, Shah J (2002) Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24:437–442CrossRefPubMedGoogle Scholar
  18. 18.
    Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ (2003) The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52:253–261CrossRefPubMedGoogle Scholar
  19. 19.
    Jung PS, Kim DY, Kim MB, Lee SW, Kim JH, Kim YM, Kim YT, Hoffman RM, Nam JH (2013) Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res 33:1029–1034PubMedGoogle Scholar
  20. 20.
    Mii S, Duong J, Tome Y, Uchugonova A, Liu F, Amoh Y, Saito N, Katsuoka K, Hoffman RM (2013) The role of hair follicle nestin-expressing stem cells during whisker sensory-nerve growth in long-term 3D culture. J Cell Biochem 114:1674–1684CrossRefPubMedGoogle Scholar
  21. 21.
    Mii S, Uehara F, Yano S, Tran B, Miwa S, Hiroshima Y, Amoh Y, Katsuoka K, Hoffman RM (2013) Nestin-expressing stem cells promote nerve growth in long-term 3-dimensional Gelfoam®-supported histoculture. PLoS One 8:e67153CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yano S, Miwa S, Mii S, Hiroshima Y, Uehara F, Yamamoto M, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, Hoffman RM (2014) Invading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imaging. Cell Cycle 13:953–960CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mii S, Amoh Y, Katsuoka K, Hoffman RM (2014) Comparison of nestin-expressing multipotent stem cells in the tongue fungiform papilla and vibrissa hair follicle. J Cell Biochem 115:1070–1076CrossRefPubMedGoogle Scholar
  24. 24.
    Tome Y, Uehara F, Mii S, Yano S, Zhang L, Sugimoto N, Maehara H, Bouvet M, Tsuchiya H, Kanaya F, Hoffman RM (2014) 3-dimensional tissue is formed from cancer cells in vitro on Gelfoam®, but not on Matrigel™. J Cell Biochem 115:1362–1367CrossRefPubMedGoogle Scholar
  25. 25.
    Kim KY, Chung BW, Yang I, Kim MB, Hoffman RM (2014) Independence of cytotoxic drug sensitivity profiles and receptor subtype of invasive ductal breast carcinoma demonstrated by the histoculture drug response assay (HDRA). Anticancer Res 34:7197–7202PubMedGoogle Scholar
  26. 26.
    Yano S, Miwa S, Mii S, Hiroshima Y, Uehara F, Kishimoto H, Tazawa H, Zhao M, Bouvet M, Fujiwara T, Hoffman RM (2015) Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging. Cell Cycle 14:808–819CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Yano S, Takehara K, Miwa S, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T, Hoffman RM (2017) GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam® histoculture. In Vitro Cell Dev Biol Anim 53:479–482CrossRefPubMedGoogle Scholar
  28. 28.
    Metildi CA, Tang CM, Kaushal S, Leonard SY, Magistri P, Tran Cao HS, Hoffman RM, Bouvet M, Sicklick JS (2013) In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody. Ann Surg Oncol 20(Suppl 3):693–700CrossRefGoogle Scholar
  29. 29.
    Metildi CA, Kaushal S, Pu M, Messer KA, Luiken GA, Moossa AR, Hoffman RM, Bouvet M (2014) Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer. Ann Surg Oncol 21:1405–1411CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Metildi CA, Kaushal S, Luiken GA, Talamini MA, Hoffman RM, Bouvet M (2014) Fluorescently-labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Surg Oncol 109:451–458CrossRefPubMedGoogle Scholar
  31. 31.
    Metildi CA, Kaushal S, Luiken GA, Hoffman RM, Bouvet M (2014) Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model. J Am Coll Surg 219:132–141CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators (2017) Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 377:1824–1835Google Scholar
  33. 33.
    Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356Google Scholar
  34. 34.
    Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:1749–1755CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Wolchok JD (2015) PD-1 blockers. Cell 162:937CrossRefPubMedGoogle Scholar
  36. 36.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sikorska H, Shuster J, Gold P (1988) Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 12:321–355PubMedGoogle Scholar
  38. 38.
    Muraro R, Wunderlich D, Thor A, Lundy J, Noguchi P, Cunningham R, Schlom J (1985) Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 45:5769–5780PubMedGoogle Scholar
  39. 39.
    Kuroki M, Greiner JW, Simpson JF, Primus FJ, Guadagni F, Schlom J (1989) Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. Int J Cancer 44:208–218CrossRefPubMedGoogle Scholar
  40. 40.
    Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J (1986) Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118–3124PubMedGoogle Scholar
  41. 41.
    Thor A, Viglione MJ, Muraro R, Ohuchi N, Schlom J, Gorstein F (1987) Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues. Int J Gynecol Pathol 6:235–247CrossRefPubMedGoogle Scholar
  42. 42.
    Wolf BC, D’Emilia JC, Salem RR, DeCoste D, Sears HF, Gottlieb LS, Steele GD Jr (1989) Detection of the tumor-associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon. J Natl Cancer Inst 81:1913–1917CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.AntiCancer, Inc.San DiegoUSA
  2. 2.Department of SurgeryUCSDSan DiegoUSA
  3. 3.San Raffaele Roma Open UniversityRomeItaly
  4. 4.IRCCS San Raffaele PisanaRomeItaly

Personalised recommendations